Stock ALDX ALDEYRA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Aldeyra Therapeutics, Inc.

Equities

ALDX

US01438T1060

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
3.97 USD +2.58% Intraday chart for Aldeyra Therapeutics, Inc. -6.59% +13.11%
Apr. 04 North American Morning Briefing : Focus Turns to -2- DJ
Apr. 03 Oppenheimer Upgrades Aldeyra Therapeutics to Outperform From Perform, $10 Price Target MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
North American Morning Briefing : Focus Turns to -2-
DJ
Oppenheimer Upgrades Aldeyra Therapeutics to Outperform From Perform, $10 Price Target
MT
Transcript : Aldeyra Therapeutics, Inc. - Special Call
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
BU
Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
CI
Aldeyra Therapeutics Insider Sold Shares Worth $580,760, According to a Recent SEC Filing
MT
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
BU
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of Rasp Platform in Systemic and Retinal Inflammatory Diseases
CI
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
BU
Aldeyra Therapeutics, Inc. and Abbvie to Enter into the Co-Development, Co-Commercialization and License Agreement
CI
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
AQ
Aldeyra Therapeutics Shares Jump as Skin Drug Shows Significant Improvement in Clinical Trial
MT
Transcript : Aldeyra Therapeutics, Inc. - Special Call
Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study
RE
Aldeyra Therapeutics' eczema drug succeeds in mid-stage study
RE
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
BU
Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
CI
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
BU
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from S&P Biotechnology Select Industry Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALDX Stock
  4. News Aldeyra Therapeutics, Inc.